cells display a largely naive-like phenotype, but express high levels of CD95, CXCR3, CD122, and LFA-1 (8
). In order to characterize the role of TSCM
cells in the generation of T cell memory in vivo, we sought to determine whether a similar subset of cells exists in NHPs. In both healthy rhesus macaques (RMs) and pigtail macaques (PTMs), we identified CD95hi
T cells in the CD45RA+
naive-like compartment (Figure A). Similarly to those in humans, NHP TSCM
cells constitute about 2%–3% of circulating CD8+
T cells (Figure B). We also identified a CD4+
subset in PBMCs, with a phenotype and frequency similar to CD8+
cells (Supplemental Figure 1, A and B; supplemental material available online with this article; doi:
). The NHP model allows a detailed examination of cellular distributions in tissues; we found that CD8+
cells from healthy RMs are most abundant in LNs, less so in the spleen and bone marrow, and are virtually absent at mucosal surfaces, i.e., the jejunum, the rectum, and the BAL, where only TCM
cells are present (Figure C). CD4+
cells displayed a similar distribution in the body, although less skewed toward the LNs (Supplemental Figure 1C). Thus, TSCM
cells have a tropism for secondary lymphoid tissues, with a distribution most similar to naive T (TN
Identification of CD8+ TSCM cells in healthy macaques.
We next investigated whether NHP TSCM
cells have features of memory cells and precede TCM
cells in terms of differentiation. Immunophenotypic analysis of activation and memory markers (8
) indicated that NHP CD8+
cells from healthy RMs are a discrete subset (Figure , A and B). Indeed, they are intermediate between TN
cells, according to the expression of proteins that are progressively upregulated (CCR5, IL-18Rα) or downregulated (CD38, CD130) with differentiation (Figure B). The human TSCM
core phenotypic markers CXCR3, CD122 (Figure , A and B), and LFA-1 (Supplemental Figure 2, A and B) were also upregulated in TSCM
cells compared with TN
cells. Unexpectedly, a relatively large proportion of TSCM
cells were proliferating (Ki-67+
) in the PBMCs (Figure A), but not in the LNs, spleen, or BM (Supplemental Figure 2C). In all sites, TSCM
cells were mostly HLA-DR negative. Similar phenotypic data were obtained for CD4+
cells (Supplemental Figure 1D).
TSCM cells from healthy RMs are phenotypically and functionally distinct T cells.
To assess the cytokine production capability of NHP TSCM cells, we stimulated PBMCs from healthy RMs with staphylococcal enterotoxin B (SEB). Following stimulation, all subsets of memory T cells produced IFN-γ, TNF, and IL-2 (Figure C). The patterns of cytokine expression show that TSCM cells differ from TCM and TEM cells, with a decreased proportion of cells producing a combination of IL-2 and TNF, but not IFN-γ, and an increased proportion of cells producing IFN-γ and IL-2 or IFN-γ only. Overall, their quality of cytokine production differed from conventional memory T cells (Figure C). TSCM cells also display attributes of memory in vivo, as proliferating (Ki-67+) TSCM cells incorporated BrdU following SIVmac239 infection in PTMs similarly to conventional TCM and TEM cells (Supplemental Figure 2D). In contrast, BrdU incorporation by TN cells was negligible.
To further assess whether TSCM cells from healthy RMs constitute discrete, less-differentiated memory cells, we evaluated their multipotency (i.e., to generate other subsets) and self-renewing capability (i.e., to maintain a TSCM phenotype) in response to TCR stimulation in vitro with αCD3/CD28 antibodies (Figure D). In the proliferating (CFSE-diluted) fraction, TSCM phenotype cells could only be recovered from sort-purified TN or TSCM cells. In addition, TSCM cells were also able to generate cells with a TCM, TEM, and terminal effector T (TTE) phenotype (Figure D). Importantly, TCM cells could not generate TSCM cells, but did generate TCM and TEM cells. Together, these data indicate that TSCM cells constitute a discrete memory subset and support the concept that TSCM cells serve as precursors of other memory cells, according to the relationship TSCM→TCM→TEM→TTE.
To determine the dynamics of antigen-specific T cell subsets during a natural infection in vivo, we enumerated SIV-specific CD8+ T cells in RMs using Mamu-A*01 pMHCI multimers presenting SIV-derived Gag CM9 or Tat-TL8 peptides (Supplemental Figure 3A). Antigen-specific TSCM cells were detected within both CM9- and TL8-specific cells at day 21 after infection, thus demonstrating that they are elicited early (Figure A). The antigen-specific TSCM cells were not merely “bystander” cells, but displayed evidence of activation (HLA-DR+, CD38bright) and proliferation (Ki-67+) (Supplemental Figure 3B). At day 21 after infection, CM9- and TL8-specific CD8+ T cells were dominated by TEM-like cells, while TSCM, TCM, and TTE cells constituted a small proportion of the total response (Figure , A and B).
Preferential maintenance of TSCM cells following escape of the cognate antigen.
The biology of the CM9 and TL8 Mamu-A*01–restricted epitopes is highly divergent. Unlike CM9, which is generally maintained intact throughout the chronic phase of infection, the TL8 uniformly undergoes escape mutation within 4–5 weeks after SIVmac239 or SIVmac251 infection in 100% of animals (12
). Tat-TL8 sequence variants do not stimulate TL8-specific T cells due to their reduced capability to bind the pMamu-A*01 class I molecule (12
) or to signal through the TCR (14
). Following TL8 escape, there is at least a 105
-fold decrease in the relative antigen load of TL8 versus CM9. Using this model, it is thus possible to investigate the relative antigen dependence of the different T cell subsets. As expected, viral escape from TL8-directed CTLs resulted in a dramatic decrease in the frequency of total circulating TL8-specific CD8+
T cells between days 21 and 70–120 after infection (Supplemental Figure 3C). Conversely, CM9-specific CD8+
T cells were maintained at high levels throughout the course of the infection (Supplemental Figure 3C). Notably, despite the near-complete elimination of antigen (extremely low levels from residual “archival,” unmutated virus may persist) (12
), TL8-specific CD8+
T cells did not disappear, but remained detectable beyond day 335 after infection (Supplemental Figure 3C).
Phenotypic analysis of the TL8-specific population revealed a significant difference in the dynamics of memory subsets in response to viral escape mutation. Indeed, the proportion of TL8-specific TEM cells decreased dramatically in favor of the less differentiated TSCM and TCM cells (Figure , A and B). By day 70 after infection, TSCM cells constituted approximately 25% of the total TL8-specific response (Figure B). In contrast, memory subset distribution within the CM9-specific CD8+ T cells remained unchanged between days 21 and 70 after infection (Figure B). Furthermore, as would be expected from a loss of antigen, TL8-specific, but not CM9-specific TSCM and TCM cells, became quiescent (Ki-67–, HLA-DR–) at day 70 after infection (Supplemental Figure 3B).
Following antigen loss, TL8-specific TCM and TEM cells underwent considerable attrition (respectively, ~10- and ~100-fold decrease in the absolute count at day 70 versus day 14), while TSCM cells did not (Figure C and Supplemental Figure 3D). Similarly, CM9-specific TSCM counts did not change over time, while the CM9-specific TCM and TEM cells contracted, albeit at markedly slower rates compared with TL8-specific CD8+ T cells (Supplemental Figure 3D), reflecting the 1-log decrease in viral load following peak viremia by day 70 after infection (i.e., establishment of the viral set point).
CM9- and TL8-specific subsets, FACS-sorted from a chronically SIV-infected RM, were fully functional as they proliferated following cognate peptide stimulation in vitro (Supplemental Figure 4A). Importantly, each T cell subset regenerated cells with the same phenotype and simultaneously derived more, not less, differentiated progeny according to the relationship TSCM→TCM→TEM (Supplemental Figure 4B), thus recapitulating the results depicted in Figure D and further demonstrating the multipotency and self-renewing capability of TSCM cells in vitro. The distribution of memory subsets observed at day 70 after infection within both the CM9- and TL8-specific populations was similar in 4 animals at more than 335 days after infection (Supplemental Figure 5A).
Following escape mutation of the TL8 epitope, the frequency of SIV-specific T cell subsets did not change in the inguinal LNs over time in 2 animals, suggesting that their lymphoid localization is not time dependent (Supplemental Figure 5B). Moreover, the same cells maintained a stable pattern of localization, as described in Figure C, during late chronic infection (Supplemental Figure 5C). Collectively, these findings indicate that TSCM cells are stable, long-lived memory cells with enhanced survival capacity compared with conventional memory cells when little or no antigen is present.
Freshly isolated CM9-specific TSCM cells were indeed less proapoptotic in vitro than TCM and TEM cells during chronic infection (Supplemental Figure 6, A and B). Similarly, fewer TL8-specific TSCM cells bound annexin V compared with the total memory fraction (there were insufficient T cells for evaluation of TL8-specific TCM and TEM cells individually; Supplemental Figure 6B). Consistent with the lack of chronic antigen exposure, TL8-specific cells were less proapoptotic than CM9-specific cells (Supplemental Figure 6B).
We thus reasoned that the preferential expression of antiapoptotic molecules in TSCM cells could be associated with their preferential survival. We could not quantify gene expression in antigen-specific cells due to their paucity. Instead, we sorted “resting” versus “blasting” (presumably antigen-responding) CD8+ T cell subsets according to their scatter properties (Supplemental Figure 7A). The “blasting” lymphocytes uniformly expressed high levels of HLA-DR, indicative of activation in vivo (Supplemental Figure 7B). Notably, genes such as LEF1 (regulating self-renewal), BCL2, and MCL1 (both antiapoptotic) were not differentially expressed among “resting” memory subsets, but were specifically upregulated to high levels in “blasting” TSCM cells (Supplemental Figure 7C).
In summary, our data show that NHP TSCM
cells are closely related to human TSCM
cells, and constitute a discrete memory T cell subset, distinct from TCM
cells, on the basis of: (a) surface immunophenotype, (b) localization in the body, (c) cytokine production, and (d) in vivo turnover. Although TCM
cells were demonstrated to possess stem cell–like properties in multiple experimental conditions (7
), our data suggest that TSCM
cells are superior to TCM
cells in this regard owing to their superior self-renewing capability and multipotency, their relative antigen dependence in vivo, and their apoptotic refractoriness. Notably, these properties are not unique to TSCM
cells, but rather are highly preferentially associated with the TSCM
subset. And importantly, the superior persistence of TSCM
cells following antigen loss suggests that they are the main precursors of T cell memory in the postantigen phase.
Maintenance of antigen-specific TSCM
cells is likely intrinsically programmed. We exclude the possibility that the TSCM
pool is maintained by the continuous recruitment of newly generated naive T cells by thymic output (15
) in our model, as thymic output is severely impaired in chronic, untreated HIV and SIV infections (16
). In addition, we find equivalent maintenance of CM9- and TL8-specific TSCM
cells despite a profound difference in antigen availability.
Our data strongly suggest that TSCM cells play a crucial role in supporting long-term cellular immunity in vivo. Future studies aimed at identifying antigen-specific TSCM cells in adoptive transfer models are required to define whether they are uniquely suited for this function. On the basis of these properties, we propose that future vaccination strategies designed to generate durable immunity should target the induction of TSCM cells. Nevertheless, cellular immunotherapy strategies will need to exploit TSCM properties to support the persistence of in vivo–transferred virus- and tumor-specific T cells.